Article
Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.
American journal of hematology - 1 Jul 2026
Tsirigotis Panagiotis, Garofalaki Maria, Lazana Ioanna, Liga Maria, Gigantes Stavros, Kopsaftopoulou Anastasia, Tziotziou Eirini, Roumelioti Anna, Tsintziloni Eleni, Hatzis Stamatios, Konstantellos Ioannis, Benetatos Leonidas, Barbarousi Despoina, Tzenou Tatiana, Asimakopoulos John V, Karagiannidi Aggeliki, Barakos George, Delimpasi Sosana, Stoumbos Dionisios, Stamouli Maria, Plata Eleni, Valera Krisela, Giannouli Stavroula, Chatzidimitriou Chrysovalantou, Gkolfinopoulou Georgia, Siakantaris Marina P, Kotsopoulou Maria, Voulgarelis Michael, Chondropoulos Spiros, Zina Vasiliki, Gkirkas Konstantinos, Kapsali Eleni, Matsouka Charis, Vassilakopoulos Theodoros P, Spyridonidis Alexandros, Angelopoulou Maria, Baltadakis Ioannis
Abstract excerpt
The prognostic value of NPM1-mut Measurable Residual Disease (MRD) has been increasingly recognized. However, real-world data validating the prognostic impact of NPM1-mut MRD remains limited. The aim of this study was to assess the prognostic value of NPM1-mut MRD and to explore optimal MRD thresholds for relapse prediction. One hundred forty-one patients with newly diagnosed NPM1-mut AML, from the Hellenic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.